BeiGene will present 31 abstracts at the European Hematology Association Congress in Milan, highlighting data from its BTK inhibitor BRUKINSA and investigational pipeline assets sonrotoclax and BGB-16673.
Ensem Therapeutics received FDA clearance for ETX-636, a first-in-class allosteric pan-mutant-selective PI3Kα inhibitor and degrader, with clinical trials set to begin in Q2 2025 for patients with PI3Kα-mutated tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.